2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists

31 March 2022 – Clinical Spotlight | Telix and Duchembio 2nd joint symposium to take place this evening (AEDT) – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists

On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA PET image interpretation for urologists in Korea.

PSMA-PET imaging has had a remarkable impact on the management of prostate cancer and has great potential to extend and improve the lives of men with this condition in Korea.

The symposium entitled: “Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists”, takes place today Thursday 31 March 2022 from 5 – 6:30 pm (KST), 7 – 8.30 pm (AEDT).

Expert speakers, Professor Mark Frydenberg, Academic Director of Urology, Cabrini Health, Australia, and Dr. Zeyad Al-Ogaili, Radiologist and Nuclear Medicine Physician, Qscan Radiology Clinics, Australia, will bring their extensive experience to a highly engaging session discussing PSMA-PET imaging in prostate cancer.

This interactive session will be moderated by Sophia Choi, Manager and Pharmacist at Duchembio, and Dr. David N. Cade, CEO Telix Asia Pacific, and will be followed by an opportunity for questions and discussion.

  • Session: Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists
  • Date: Thursday, 31 March 2022
  • Time: 5:00 – 6:30 pm KST / 7:00 – 8:30 pm AEDT

There is still an opportunity to register! If you are interested in attending this event or would like to know more, please contact Duchembio Sales & Marketing at +822-332-4868 and select Extension 1.

We hope you find this symposium interesting and informative and look forward to seeing you there!

To return to the Telix homepage please click here.